Moneycontrol
HomeNewsTrendsHealthCoronavirus pandemic | Centre to expedite clearances to bulk drug projects to fight COVID-19
Trending Topics

Coronavirus pandemic | Centre to expedite clearances to bulk drug projects to fight COVID-19

The notification has been sent to the Central Pollution Control Board, Expert Appraisal Committee and pollution control boards in all states and Union territories.

March 12, 2020 / 18:34 IST
Story continues below Advertisement

As cases of novel coronavirus rise, the Centre on March 12 decided to expedite clearances to bulk drug projects by considering them "out of turn". In a notification, the Environment Ministry said the expeditious environmental clearances given to units involving active pharmaceutical ingredients (API) and bulk drug intermediates will ensure overall preparedness and availability of drugs to reduce the impact of the outbreak.

"In order to ensure drug availability/production to reduce the impact of the outbreak of Novel Corona virus (COVID-19) and to improve overall preparedness of drugs, the ministry hereby directs projects or activities in respect of Bulk drugs (API and bulk drug intermediates) shall be considered out of turn and clearances shall be issued expeditiously," the notification issued by Sharath Kumar, scientist at the ministry's Impact Assessment division, said.

Story continues below Advertisement

The notification has been sent to the Central Pollution Control Board, Expert Appraisal Committee and pollution control boards in all states and Union territories.

The number of coronavirus patients in India has risen to 73 with 13 fresh cases, including nine from Maharashtra and one each from Delhi, Ladakh, and Uttar Pradesh as well as one foreign national.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show
PTI
first published: Mar 12, 2020 06:28 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!